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Background/aim: Sp1 polymorphism of type I collagen genes is accompanied with bone collagen disorders and severe clinical phenotypes
such as osteogenesis imperfecta. The aim of this study was to study the association between COLIA1 Sp1 polymorphism and bone density
rate.
Materials and methods: In this descriptive, analytical study conducted in 2013 in southwestern Iran, 200 blood samples, per the
Cochran sample size formula, were taken from women aged 45 and older. DNA was extracted from the samples using the phenol–
chloroform method and the genomic fragments in question were proliferated using the polymerase chain reaction (PCR) method.
Results: The genotype distribution of Sp1 polymorphism for the SS, Ss, and ss genotypes was 57.1%, 31.4%, and 11.4%, respectively, in
the control group and 9.2%, 75.4%, and 15.4%, respectively, in the patients. Statistically, Sp1 polymorphism in patients had a significant
deviation (P = 0.001, χ2 = 34.25) and there was no Hardy–Weinberg equilibrium. In the control group, there was no significant deviation
for Sp1 polymorphism (P = 0.226, χ2 = 2.97). Sp1 polymorphism was significantly associated with bone density. Women with the SS
genotype had the highest bone density.
Conclusion: Sp1 gene polymorphism is associated with bone density rate in women aged 45 and over, and is more commonly observed in
homozygosity. Determining this genotype’s polymorphism is valuable to identify the women at risk of developing osteoporosis.
Key words: Bone mineral density, collagen type 1α1 Sp1 polymorphism, osteoporosis, polymerase chain reaction

1. Introduction
Osteoporosis is a common skeletal disorder that is
accompanied by a decrease in bone mass, deterioration of
bone microstructures, and an increase in susceptibility to
fracture (1). Osteoporosis has a complex etiology and is
considered to be a multifactorial polygenic disease with
genetic factors alongside hormonal, environmental, and
nutritional ones contributing to its incidence (2).
Fracture leads to increases in morbidity and mortality
and imposes high costs on individuals and society. On
average, one of every three women and one of every 12
men develop fractures during their lifetime (3,4).
One of the conditions causing osteoporosis is a
postmenopausal decrease in estrogen. After 35 years, the
amount of bone density gradually declines in both men and
women, but since estrogen decreases in postmenopausal
women, their bone mass declines more rapidly compared
to men, so that 5–10 years after menopause one third of
the bone density is lost. In ages over 65 years, the amount
* Correspondence: razieh_jaktaji@yahoo.com
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of bone loss equalizes in women and men and bone mass
continues to decline until death (1,5). Genetic differences
are likely to have a role in bone mineral density (BMD)
diversity in different ethnicities (6).
An extracellular matrix is the main component of bone
and develops a scaffolding and three-dimensional network
from collagen type I, on which minerals precipitate (7).
Collagen is a fibrous protein that comprises about 30% of
body weight and is frequently seen in connective tissues
like bones, tendons, and skin. This protein has an important
contribution to wound healing, cell proliferation, cell
differentiation, and cell migration. Proteins of the collagen
family are the most frequent proteins of the extracellular
matrix (8,9).
Collagen type I is the main collagen and the highest
protein in the bone matrix, comprising approximately 80%
of the total bone tissue’s proteins. Variations in collagen
characteristics and the relative amount in the bone matrix
could influence the mechanical properties of the bone
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tissue and cause fragility and increased susceptibility to
fracture. Collagen consists of two chains, alpha 1 and alpha
2 (at a 2:1 ratio in the collagen fibers), which are encoded
by two different genes, collagen type 1α1 (COLIA1) and
collagen type 1α2 (COLIA2) (10–12). The gene COLIA1
is on the long arm of chromosome 17 (17q21–22) and has
51 exons; the gene COLIA2 is on chromosome 7 and has
52 exons (13). An imbalanced ratio of collagen chains
could be a potential risk factor for bone fragility and a
predisposing factor for osteoporosis (12).
Different polymorphisms have been described in several
genes (14). Although many studies have been conducted
to date, the unique contributions of each one of these
polymorphisms to osteoporosis pathogenesis have still
remained unconfirmed worldwide (15).
COLIA1 and COLIA2 mutations are accompanied by
bone collagen disorders and severe clinical phenotypes
including osteogenesis imperfecta. A substitution
mutation of G/T in intron 1 of gene COLIA1 (rs 1800012,
G>T substitution) probably influences gene transcription,
resulting in a variation in the alpha 1 sequence/alpha 2
sequence ratio and collagen adult protein; this is called
COLIA1 Sp1 polymorphism (16,17).
The genotypes of COLIA1 Sp1 consist of SS, Ss, and
ss. Allele s inheritance is recessive. The presence of allele
s increases the tendency toward Sp1 transcription factor.
The ratio of collagen α1(I) to α2(I) was 2.3 to 1 in Ss
heterozygotes compared with the expected value of 2 to 1 in
SS homozygotes (18). (For osteoblasts of homozygous SS, the
alpha 1/alpha 2 ratio is similar to the rate in question, i.e. 2
to 1). The variation in the alpha sequence ratios is due to the
increase in mRNA COLIA1 compared to mRNA COLIA2.
As a result, the strength of a heterozygous Ss individual’s
bone declines in comparison to one with homozygous SS.
Homozygous ss has the least bone density with a higher risk
of fracture. Of course, this polymorphism is more associated
with vertebral and wrist fractures. In gene COLIA1, there
are other polymorphisms that are associated with bone
density, including PCOL2, which causes G/T substitution in
the promoter region (12,17,19).
Recent advances in detecting the genetic basis of
diseases have opened new horizons, and disease diagnosis
through determining genotype is gradually increasing.
The pharmacologic and interventional methods for

preventing osteoporosis in the individuals at risk
add to the significance of the issue. Different studies
have demonstrated the association of COLIA1 Sp1
polymorphism with bone density rate (20), but no such
association has been specified in Iranians. Since no study,
to the best of our knowledge, has yet been done on the
association of osteoporosis having a molecular basis with
this polymorphism, this study aimed to investigate the
association between Sp1 polymorphism and bone density
rate in women aged 45 and over in an accessible Iranian
subpopulation.
2. Materials and methods
In this descriptive, analytical study conducted between
December 2012 and September 2013, blood samples were
taken for bone density measurement from women aged 45
and over in referring centers in southwestern Iran, based
on convenience sampling.
In this study, the age of 45 was regarded as the age of
onset of menopausal changes (21).
In this study, 200 samples were investigated. Sample
size was calculated using the Cochran equation. Exclusion
criteria included corticosteroid consumption history,
ovariectomization or premature ovarian failure, thyroid
disease, calcium intake disorders, and gastrointestinal and
renal diseases.
After consent was obtained from the participants and
questionnaires related to clinical data were filled out, a 5
mL sample of peripheral blood was taken from each patient
and put in tubes containing EDTA (0.5 M). The blood
samples were sent to the Cellular and Molecular Research
Center of Shahrekord University of Medical Sciences for
molecular analysis. For this, DNA was extracted using the
phenol–chloroform method (22). The quality, quantity,
concentration, and purity of the extracted DNA were
examined by spectrophotometry.
The chain relevant to the collagen 1 gene was
extracted from the NCBI database (23). The primers for
Sp1 polymorphism were designed using Primer3, which
examines the primers in terms of primer–dimer formation
or their self-supplementation and provides the operator
with the best chain. The primers used are shown in Table 1.
Polymorphism proliferation was done by polymerase
chain reaction (PCR). In the present study, for proliferation

Table 1. The primer chains used in this study.
Tm

Primer type

5´–3´ primer sequences

70

F

CTGGACTATTTGCGGACTTTTTGG

60

R1

GGCGAGGGAGGAGAGAAG

68

R2

GTCCAGCCCTCATCCTGGCC
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of the regions in question and PCR conduction, firstly the
main reaction solution was prepared in a microtube (vial).
At this step, the DNA sample was not added to the solution.
After distributing the solution among the special PCR vials,
we added the necessary amount of DNA sample to them.
In each PCR analysis, a vial was regarded as a negative
control that indicated lack of material contamination with
the DNA sample. The final volume of reaction solution was
considered to be 25 µL in each microtube. A thermocycler
(PC818, ASTEC, Japan) was used.
For separation, identification, and purification of the
DNA fragments, an electrophoresis technique on 8%
polyacrylamide gel was used with TBE and loading X6
(Fermentas) buffers (24). The fragments were dissolved
using restriction enzymes (Fermentas). The detection
of DNA size was done with a ready-to-use GeneRulerTM
DNA ladder. Silver nitrate staining was used to observe the
obtained bands. The data were analyzed using SPSS with
the chi-square and analysis of variance (ANOVA) tests.
3. Results
Considering that all women over 45 years old have
some proportion of bone density decline, we assigned
the individuals with normal bone density and/or mild
osteopenia as the control group (comprising 70 individuals)
and those with severe osteopenia and osteoporosis as the
patient group (consisting of 130 individuals), based on
radiograph t-scores (Table 2). In this study, a t-score >
–1 was determined as normal, a t-score ≤ –1 to ≥ –2
as mild osteopenia, a t-score < –2 to ≥ –2.5 as severe
osteopenia, and a t-score < –2.5 as osteoporosis (25).
To investigate the quality and quantity of the extracted
DNA, NanoDrop was used. In most cases, the quality
of the extracted DNA samples was desirable and had an
A260/A280 value between 1.75 and 2.

For Sp1 polymorphism, the PCR reaction is a
seminested type; that is, through the first step of the
PCR, the fragment containing Sp1 polymorphism is
proliferated. The size of the fragments yielded by PCR
of the Sp1 polymorphism gene COLIA1 in the first step
was 287 bp; the second PCR was conducted on the 287
bp product obtained from the first PCR and the cutting
site was developed using the second PCR. The size of the
fragments obtained from the second PCR was 254 bp.
From enzymatic dissolution of Sp1 polymorphism of the
collagen gene by enzyme restrictor MscI, two fragments of
18 and 236 bp were developed. The 18 bp fragment had a
high speed because of its small size and it is not observed
in Figure 1.
Genotype and allele frequency were calculated for the
polymorphism in question in the two groups. To examine
the difference in genotypic frequency between the patients
and the control group, chi-square and ANOVA tests were
used. The confidence interval (CI) was set to 95% in all
experiments and P < 0.05 was considered significant
(Tables 3 and 4).
The chi-square test was independently calculated for
the patients and control group with a degree of freedom of
2 for the polymorphism in question. The P value for Sp1
polymorphism in the patients was calculated as 0; that is,
statistically there was a significant deviation for the Sp1
polymorphism and no Hardy–Weinberg equilibrium was
noted (P = 0.001, χ2 = 34.25). In the control group, the P
value obtained was 0.266; that is, in the control group there
was no significant deviation for Sp1 polymorphism and a
Hardy–Weinberg equilibrium was seen (P = 0.226, χ2 =
2.97).
The ANOVA test indicated a significant difference in
the Sp1 polymorphism between the control group and the
patients.

Table 2. Characteristics of the control and patient groups in this study.
Variable

Mean ± SD
(patients)

Mean ± SD
(control group)

Number

130

70

Lumbar vertebrae t-score

2.8- ± 0.67

0.9- ± 0.8

< 0.0001

Femoral neck t-score

1.3- ± 0.78

0.34- ± 0.5

< 0.0001

Age (years)

59.9 ± 8.4

51.3 ± 5.7

< 0.0001

Height (cm)

154.8 ± 3.6

158.5 ± 4.9

< 0.0001

Weight (kg)

66.3 ± 8.09

71.7 ± 9.1

< 0.0001

Lumbar vertebrae BMD* (g/cm2)

0.73 ± 0.1

0.92 ± 0.15

< 0.0001

Femoral neck BMD (g/cm2)

0.76 ± 0.1

0.88 ± 0.11

< 0.0001

* = Bone mineral density.
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Figure 1. A: PCR product of Sp1 polymorphism in the second step (the size of the
proliferated section was 254 bp). B: The results relevant to enzymatic dissolution of
Sp1 polymorphism. M = DNA size marker, C+ = positive control, and C– = negative
control. The samples numbered 1 and 3 have homozygous genotype ss, the samples
numbered 2 and 5 have homozygous genotype SS, and the samples numbered 4, 6,
7, 8, 9, and 10 have heterozygous genotype Ss.
Table 3. Sp1 genotype and allele frequency in the two groups.
Sp1 polymorphism
of the collagen gene

Genotypes

Genotypic frequency

OR (95% CI)

P value

12 (9.2%)

2.69 (1.47–4.93)

<0.0001

22 (31.4%)

98 (75.4%)

0.64 (0.32–1.29)

0.17

ss

8 (11.4%)

20 (15.4%)

1.00

Total

70 (100)

130 (100%)

Control group

Patients

SS

40 (57.1%)

Ss

Allelic frequency
Alleles

S

0.73 (73%)

0.47 (47%)

1.80 (1.28–2.53)

s

0.27 (27%)

0.53 (53%)

1.00

Total

1 (100%)

1 (100%)

<0.0001

Table 4. The number of expected and observed individuals for Sp1 polymorphism in the two groups.
Patients

Sp1 polymorphism
of the collagen gene

Genotypes

observed

expected

OR
(95% CI)

SS

12

28.7

0.82 (0.45–1.48)

Ss

98

64.8

1.68 (1.16–2.44)

ss

20

36.5

1.00

Total

130

130

Control group
observed

expected

OR
(95% CI)

0.52

40

37.3

0.84 (0.52–1.36)

0.54

0.003

22

27.6

0.71 (0.42–1.22)

0.41

8

5.1

1.00

70

70

P value

P value
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The mean t-score for the lumbar vertebrae was –2.425 in
12 patients with genotype SS, –2.761 in 98 with genotype Ss,
and –3.395 in 20 patients with genotype ss. The df for both
lumbar vertebrae and femoral neck was 2 while the P value
for lumbar vertebrae was 0.00 and that of femoral neck 0.007,
indicating that the Sp1 polymorphism was significantly
associated with t-score, i.e. bone density. The individuals
with genotype SS had the highest density, followed by the
individuals with genotypes ss and Ss (Table 5).
4. Discussion
Polymorphism or multiformity is a change in nucleotides
in a gene sequence that leads to no particular disease and
has a frequency of higher than 1% in the communities.
In fact, this polymorphism can develop or destroy an
enzyme’s identifying site and develop various genotypes
(26). The results of the present study highlight that Sp1
polymorphism is an important index for low bone mass
and vertebrae fracture and determining the genotypes of
this polymorphism is likely to be valuable in identifying
the women at risk of osteoporosis (27).
Different studies on the association of polymorphism
of several genes with osteoporosis have been conducted,
including the vitamin D receptor gene, collagen type
1, calcitonin receptor, insulin-like growth factor, and
interleukin 6 (28).
In the present study, the association of Sp1
polymorphism of the collagen gene with bone density
was investigated in women aged 45 and older. In view of
the obtained results, homozygous ss and heterozygous
Ss individuals had the lowest t-scores, lower in the
homozygous ss individuals compared to the heterozygous
Ss. There is a significant association between bone
density and Sp1 polymorphism of the collagen gene and
a statistically considerable difference in genotype and
allelic frequency was observed between the patients and
the control group (P < 0.05). In the patients with severe
osteoporosis and vertebral fracture, genotypes ss and Ss
are prevalent (approximately 54%) (29,30).

In the present study, older patients were shorter and
thinner and the BMD of these individuals was lower
compared to the control group. Some other researchers
obtained similar results. For example, in a study on British
women, this polymorphism was associated with BMD. As
such, BMD in the homozygous genotype SS was higher
than in the heterozygous genotype Ss and the homozygous
genotype ss (29).
Langdahl et al. investigated the association of Sp1
polymorphism of the collagen gene osteoporosisassociated fractures in Danish men and women and found
that Sp1 polymorphism of COLIA1 was notably associated
with lumbar vertebral fractures in both men and women
(31).
Inconsistent findings have been obtained on the
association between Sp1 polymorphism of the collagen
gene and osteoporosis-related fractures in Caucasian
postmenopausal women (32–35). The results of four metaanalyses in this field indicated that Sp1 polymorphism
of COLIA1 gene is associated with osteoporosis-related
fractures and BMD in Caucasian postmenopausal women
(18,27,36,37). This polymorphism contributes importantly
to osteoporosis pathogenesis, which is mediated by affecting
BMD and other predictors of osteoporosis-associated risk
of fracture such as the ultrasound characteristics of bone
and skeletal geometry (38).
One of the above meta-analyses is indicative of an
association between the presence of the s allele of Sp1
polymorphism and a decline in BMD of the lumbar
vertebrae and femoral neck, and an increase in vertebral
fracture (36). Ralston et al. argued that fracture risk in
individuals with the homozygous ss genotype was about
40% higher than that in those with the genotype SS (39).
Ji et al. conducted a study on menopausal Caucasian
women and concluded that Sp1 polymorphism was likely
to be associated with osteoporotic fracture (40). A study
in Turkey indicated that bone density in the individuals
with genotype Ss was lower compared to those with
genotype SS (41), consistent with the present study. Some

Table 5. The relationship between Sp1 polymorphism and t-score.
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T-score
(Mean ± SD)

Genotypes

Number

Standard error

P value

Lumbar
vertebrae

SS
Ss
ss

12
98
20

–2.425 ± 0.48
–2.761 ± 0.64
–3.395 ± 0.62

0.13
0.06
0.13

0.001

Femoral
neck

SS
Ss
ss

12
98
20

–1.250 ± 0.55
–1.300 ± 0.81
–1.850 ± 0.55

0.16
0.08
0.12

0.007
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researchers have obtained opposite results. For example,
in a study of postmenopausal Swedish women, Liden
et al. argued that COLIA1 Sp1 polymorphism was not
significantly associated with femoral neck BMD, but closely
associated with vertebral fracture (42). In an investigation
by McClean et al. in Northern Ireland, osteoporosisassociated fractures and Sp1 were not associated (43).
Bandres et al. investigated the association between BMD
and COLIA1 in Spanish postmenopausal women and
stated that although no association was found between
COLIA1 and BMD, this gene was significantly associated
with the prevalence of osteoporotic fractures. This should
be examined in a larger sample size (44). The association
between osteoporosis and Sp1 polymorphisms (COLIA1)
in postmenopausal women in Turkey was investigated
and no statistically considerable difference in genotype
and allelic frequency was observed between the patients
and the control group (45). As stated by Bandres et al., in
studies in which opposite results were obtained, a small
sample size was offered as the reason. The other reason
for this inconsistency could be the study of different races.
In view of the numerous potentially identifiable genetic

markers and clinical outcomes to which these may be
related, testing and validation of statistical hypotheses in
genetic epidemiology is an unprecedented task (27).
Since collagen I has numerous polymorphisms, it
is recommended that the association of other collagen I
polymorphisms with bone density be examined to achieve
a complete haplotype. The association of bone density with
other polymorphisms involved in osteogenesis regulation
should be studied as well.
Sp1 gene polymorphism is associated with bone
density rate in women aged 45 and over, more commonly
observed in homozygosity. Determining this genotype’s
polymorphism is valuable to identify the women at risk of
developing osteoporosis.
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